Tag: 300-400

High performance volatile polymeric memory devices based on novel triphenylamine-based polyimides containing mono- or dual-mediated phenoxy linkages was written by Kuorosawa, Tadanori;Chueh, Chu-Chen;Liu, Cheng-Liang;Higashihara, Tomoya;Ueda, Mitsuru;Chen, Wen-Chang. And the article was included in Macromolecules (Washington, DC, United States) in 2010.Recommanded Product: 1-Iodo-4-(4-nitrophenoxy)benzene The following contents are mentioned in the article:

Two novel functional polyimides (PIs), PI(AAPT-TPA) and PI(APT-TPA), consisting of electron-donating 4-amino-4′-(p-aminophenoxy)-triphenylamine (AAPT) or 4,4′-bis(p-aminophenoxy)-triphenylamine (APT) and electron-accepting phthalimide moieties, were prepared for the memory device applications. The TPA moieties as electron donor are expected to enhance the electron donating and charge transport ability with phthalimide moieties (electron acceptor). The monophenoxy linkage PI(AAPT-TPA) had a higher T_g and a lower band gap than the dual-phenoxy linkage PI(APT-TPA). It suggested the more rigid backbone of the former and led to different memory characteristics. The memory devices with the configuration of ITO/PI/Al exhibited two conductivity states and could be swept pos. or neg. with a high ON/OFF current ratio of 10⁸-10⁹. The PI(AAPT-6FDA) device relaxed from the ON state to the OFF state quickly after the applied voltages was removed, whereas the ON state of the PI(APT-6FDA) device could remain for around 4 min after the power was turned off. Probably dynamic random access memory (DRAM) was exhibited for the PI(AAPT-6FDA) device and static random access memory (SRAM) was for the PI(APT-6FDA) device. The volatile memory characteristics were probably attributed to the unstable charge transfer (CT) complex based on the weak theor. dipole moments of the studied PIs. The dual-mediated phenoxy linkage of PI(APT-6FDA) led to the more twisted conformation compared to the monosubstituted PI(AAPT-6FDA) based on the theor. anal. by the d. functional theory (DFT) method. It thus produced a potential barrier for delaying the back CT process by the elec. field and explained the SRAM characteristic. The present study suggested the importance of the TPA structure for the memory characteristics. The fast switching and high ON/OFF characteristics also indicated the new TPA based polyimides for advanced memory technol. This study involved multiple reactions and reactants, such as 1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1Recommanded Product: 1-Iodo-4-(4-nitrophenoxy)benzene).

1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1) belongs to iodide derivatives. Indole produced by Proteus, Pseudomonas, Escherichia and other species was shown to be a growth promoting factor in Arabidopsis thaliana.Indole was synthesized in moderate yield via an o-naphthoquinone catalyzed tandem cross-coupling of substituted aniline and benzylamine under aerobic oxidation conditions.Recommanded Product: 1-Iodo-4-(4-nitrophenoxy)benzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Substitution products of 4-nitro- and 4-acetamidodiphenyl ether was written by Scarborough, Harold A.. And the article was included in Journal of the Chemical Society in 1929.Name: 1-Iodo-4-(4-nitrophenoxy)benzene The following contents are mentioned in the article:

4-ClC₆H₄OC₆H₄NO₂-4 (I), m. 76°, results from 4-O₂NC₆H₄OPh (II) and Cl in AcOH or from p-O₂NC₆H₄Cl and p-ClC₆H₄OK; the 4-Br derivative (III), m. 61°, was prepd, similarly. 4-NO₂CdH₄OPh and ICl in AcOH give 4-iodo-4′-nitrodiphenyl ether (IV), pale yellow, m. 71°; Cl precipitates a stable iodochloride, yellow. II or III in dry Br or p-ClC₆H₄NO₂ and 2,4-Br₂C₆H₃OK give 2,4-dibromo-4′-nitrodiphenyl ether, m. 81°. Reduction of II in EtOH- or Et₂O-HCl with SnCl₂ gives 4-aminodiphenyl ether-HCl, m. 238°; the Ac derivative, m. 127°. Reduction of I gives the NH₂ derivative, m. 101°, whose Ac derivative (V), m. 146°. Nitration of V gives the 3-NO₂ derivative, yellow, m. 98°; hydrolysis gives 4′-chloro-3-nitro-4-aminodiphenyl ether, m. 114°; deamination gives 4′-chloro-3-nitrodiphenyl ether, yellow, m. 60°. 4-Bromo-4′-acetaminodiphenyl ether, m. 161°; nitration gives 4′-bromo-3-nitro-4-acetaminodiphenyl ether, yellow, m. 107°; hydrolysis gives the free NH₂ derivative, scarlet, m. 144°; deamination gives 4′-bromo-3-nitrodiphenyl ether, yellow, m. 64°. 4-Iodo-4′-aminodiphenyl ether, m. 91°; Ac deriv; m. 174°. 4′-Iodo-3-nitro-4-acetaminodiphenyl ether, yellow, m. 123°; hydrolysis gives the free NH₂ derivative, scarlet, m. 155°. 3-Nitro-4-aminodiphenyl ether, bright red, m. 82°; Ac derivative, deep yellow, m. 100°. 2,4-Dibromo-4′-acetaminodiphenyl ether, m. 158°; 3′-NO₂ derivative, yellow, m. 141°; the free NH₂ derivative, yellow, m. 107°; deamination gives 2,4-dibromo-3′-nitrodiphenyl ether, orange, m. 72°. 4-Iododiphenyl ether, m. 48°; dichloride, yellow. 4-Bromo-4′-iododiphenyl ether, m. 72°. 4,4′-Diiododiphenyl ether, m. 139°. This study involved multiple reactions and reactants, such as 1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1Name: 1-Iodo-4-(4-nitrophenoxy)benzene).

1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1) belongs to iodide derivatives. Indole could be stereoselectively alkylated with chiral cyclopentyl sulfone reagent. More than 200 indole derivatives have already been marketed as drugs or are under advanced stages of clinical trials.Name: 1-Iodo-4-(4-nitrophenoxy)benzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Decomposition of the salts of p-X-benzenediazonium complexes by 18-crown-6 in p-iodoanisole was written by Eustathopoulos, Helene;Court, Jean;Lambeaux, Claude;Bonnier, Jane Marie. And the article was included in Nouveau Journal de Chimie in 1985.Safety of 1-Iodo-4-(4-nitrophenoxy)benzene The following contents are mentioned in the article:

The decomposition of para-substituted benzenediazonium ions complexed with 18-crown-6 has been studied. Anal. of the reaction products from the thermal decomposition of the complexed diazonium salts in p-iodoanisole solution showed that the nature of the para substituent drastically changed the reaction mechanism. The decomposition of the complex p-nitrobenzenediazonium ion proceeds through a radical pathway. In addition to isomeric (p-nitrophenyl)iodoanisoles, the decomposition affords 2,4′-dimethoxy-5-iodobiphenyl and 5,4′-dimethoxy-2-iodobiphenyl, which result from the attack of p-iodoanisole by p-anisidyl radicals derived from the 4-methoxy-4′-nitrophenyliodinyl radical. 4-Iodo-4′-nitrodiphenyl ether and 4-methoxy-4′-nitrobiphenyl could not be detected; therefore, with a strong electron-withdrawing substituent, the decomposition mechanism is exclusively homolytic. The thermal decomposition of the complexed p-chlorobenzenediazonium salt affords products derived from the reaction of the p-chlorophenyl cation and products derived from the reaction of the p-chlorophenyl radical. At [crown ether]/[p-ClC₆H₄N₂⁺] = 6, the homolysis represents at least 30% of the total decomposition This study involved multiple reactions and reactants, such as 1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1Safety of 1-Iodo-4-(4-nitrophenoxy)benzene).

1-Iodo-4-(4-nitrophenoxy)benzene (cas: 21969-05-1) belongs to iodide derivatives. Indole is an important structural motif of various drugs, therapeutic leads besides its prevalence in numerous natural products, agrochemicals, perfumery, and dyes. More than 200 indole derivatives have already been marketed as drugs or are under advanced stages of clinical trials.Safety of 1-Iodo-4-(4-nitrophenoxy)benzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On June 7, 2007, Naidu, B. Narasimhulu; Banville, Jacques; Beaulieu, Francis; Connolly, Timothy P.; Krystal, Mark R.; Matiskella, John D.; Ouellet, Carl; Plamondon, Serge; Remillard, Roger; Sorenson, Margaret E.; Ueda, Yasutsugu; Walker, Michael A. published a patent.Computed Properties of 70931-59-8 The title of the patent was Bicyclic heterocycles, particularly 4-oxopyrimido[2,1-c][1,4]oxazine-2-carboxamide and 4-oxopyrimido[2,1-c][1,4]oxazepine-2-carboxamide derivatives, as HIV integrase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. And the patent contained the following:

The invention is related to bicyclic pyrimidinone compounds, e.g. pyrimidooxazine I, which inhibit HIV integrase and prevent viral integration into human DNA. The invention is also related to the preparation of pharmaceutical compositions comprising a therapeutically effective amount of bicyclic pyrimidinones and a pharmaceutically acceptable carrier, optionally including a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection, as well as to the use of the compositions for the treatment of those infected with HIV. Thus, hydrogenolysis of dibenzyl compound II gave phosphonic acid I. I was tested for HIV integrase inhibition and for inhibition of HIV replication. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Computed Properties of 70931-59-8

The Article related to pyrimidinone bicyclic preparation hiv integrase inhibitor, oxopyrimidooxazine oxopyrimidooxazepine carboxamide preparation hiv integrase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 70931-59-8

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On February 17, 2009, Naidu, B. Narasimhulu; Sorenson, Margaret E.; Digiugno, Dawn published a patent.Formula: C7H5BrFI The title of the patent was Preparation of bicyclic heterocycles, particularly pyrimido[2,1-c][1,4]oxazine-2-carboxamides, as HIV integrase inhibitors. And the patent contained the following:

The invention is related to the preparation of title compounds I [R1 = C1-6(Ar1)alkyl, C1-6(Ar1)oxyalkyl, C1-6(Ar1)hydroxyalkyl, etc.; R2 = H, alkyl, OH, alkyloxy; Ar1 = (un)substituted Ph, naphthyl, benzothiophenyl, etc.; X-Y-Z = C(R3)2OC(R3)2, C(R3)2OC(R3)2C(R3)2, C(R3)2C(R3)2C(R3)2C(R3)2; R3 = H, alkyl], and their pharmaceutically acceptable salts or solvates which inhibit HIV integrase and prevent viral integration into human DNA. The invention is also related to the pharmaceutical compositions comprising pyrimidinones I, and methods of using them for treating HIV infection and AIDS. Thus, reacting ester II (preparation given) with 4-fluorobenzylamine in DMF/ethanol in the presence of TEA at 90掳 gave amide III in 82% yield. Selected I displayed IC50 values in the range of 0.002-0.1 渭M for the inhibition of HIV integrase activity. III demonstrated synergistic or additive-synergistic HIV antiviral activity when used in combination with other antiviral agents, e.g., zidovudine, indinavir, T-20, etc. Crystalline forms of III were prepared (crystal data were given). The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Formula: C7H5BrFI

The Article related to bicyclic heterocycle hiv integrase inhibitor preparation, pyrimidooxazine carboxamide preparation hiv integrase inhibitor aids treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C7H5BrFI

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On September 7, 2006, Naidu, B. Narasimhulu; Banville, Jacques; Beaulieu, Francis; Connolly, Timothy P.; Krystal, Mark R.; Matiskella, John D.; Ouellet, Carl; Plamondon, Serge; Remillard, Roger; Sorenson, Margaret E.; Ueda, Yasutsugu; Walker, Michael A. published a patent.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene The title of the patent was Preparation of bicyclic heterocycles, particularly pyrimido[2,1-c][1,4]oxazine-2-carboxamides, as HIV integrase inhibitors. And the patent contained the following:

The invention is related to the preparation of title compounds I [R1 = C1-6(Ar1)alkyl, C1-6(Ar1)oxyalkyl, C1-6(Ar1)hydroxyalkyl, etc.; R2 = H, alkyl, OH, alkyloxy; Ar1 = (un)substituted Ph, naphthyl, benzothiophenyl, etc.; X-Y-Z = C(R3)2OC(R3)2, C(R3)2OC(R3)2C(R3)2, C(R3)2C(R3)2C(R3)2C(R3)2; R3 = H, alkyl], and their pharmaceutically acceptable salts or solvates which inhibit HIV integrase and prevent viral integration into human DNA. The invention is also related to the pharmaceutical compositions comprising pyrimidinones I, and methods of using them for treating HIV infection and AIDS. Thus, reacting ester II (preparation given) with 4-fluorobenzylamine in DMF/ethanol in the presence of TEA at 90掳 gave amide III in 82% yield. Selected I displayed IC50 values in the range of 0.002-0.1 渭M for the inhibition of HIV integrase activity. III demonstrated synergistic or additive-synergistic HIV antiviral activity when used in combination with other antiviral agents, e.g., zidovudine, indinavir, T-20, etc. The experimental process involved the reaction of 1-(Bromomethyl)-4-fluoro-2-iodobenzene(cas: 70931-59-8).Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

The Article related to bicyclic heterocycle hiv integrase inhibitor preparation, pyrimidooxazine carboxamide preparation hiv integrase inhibitor aids treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 1-(Bromomethyl)-4-fluoro-2-iodobenzene

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On March 20, 2008, Flynn, Daniel L.; Kaufman, Michael D.; Patt, William C.; Petillo, Peter A. published a patent.Safety of Ethyl 5-chloro-2-iodobenzoate The title of the patent was Preparation of heterocyclic ureas as kinase inhibitors useful for the treatment of proliferative and inflammatory diseases. And the patent contained the following:

The present invention relates to novel kinase inhibitors and modulators of general formula I (wherein E1 is cyclopropyl, furyl, Ph, etc.; A is Ph, naphthyl, indanyl, etc.; Z6 is H, C1-C6alkyl, branched C3-C7alkyl, etc.; R3 and R16 are H, C1-C6 alkyl, branched C3-C7alkyl, etc.; R4 is H, C1-C6alkyl, hydroxyC1-C6alkyl, etc.; X2 is a direct bond or (un)branched C1-C6 alkyl; t is 1-3) useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration. Example compound II was prepared by reacting 2-amino-6-(3-amino-4-fluorophenyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (preparation given) and 3-tert-butyl-1-phenyl-1H-pyrazol-5-amine (preparation given). In general, the I tested exhibited >50 % inhibition activity at 0.2-2 渭M concentration in V600E B-Raf kinase and C-Raf kinase assays. In general, the I tested exhibited >50 % inhibition of proliferation at 1-10uM concentration against A375 cells. The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).Safety of Ethyl 5-chloro-2-iodobenzoate

The Article related to heterocyclic urea kinase inhibitor preparation proliferative inflammatory disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of Ethyl 5-chloro-2-iodobenzoate

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On October 15, 2015, Loso, Michael R.; Gustafson, Gary D.; Kubota, Asako; Yap, Maurice C.; Buchan, Zachary A.; Steward, Kimberly M.; Sullenberger, Michael T.; Hoekstra, William J.; Yates, Christopher M. published a patent.COA of Formula: C7H3BrF3I The title of the patent was Preparation of metalloenzyme inhibitor compounds as fungicides for pharmaceutical and agricultural use. And the patent contained the following:

The invention describes compounds of formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes as well the use of I to protect and/or cure plants against damage caused by agriculturally relevant fungi. I [wherein Z is (un)substituted pyrimidinyl, thiazolyl, oxazolyl, etc.; R1 is alkyl, haloalkyl, (hetero)aryl, etc.; R2 is aryl or heteroaryl; R3 is H, alkyl, (hetero)aryl, etc.; R4, R5, R6, and R7 are independently H, alkyl, alkoxy, etc.] are claimed and exemplified. Coupling of 1-(4-bromophenyl)-2,2-dimethyl-1-(pyrimidin-5-yl)propan-1-ol with (4-(trifluoromethoxy)phenyl)boronic acid provided II in 93% yield. Candidate compounds of I were evaluated for fungicidal activity against Leaf Blotch of Wheat (Mycosphaerella graminicola; Anamorph; Septoria tritica; Bayer Code SEPTTR)(data given). The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).COA of Formula: C7H3BrF3I

The Article related to metalloenzyme inhibitor preparation pharmaceutical agricultural fungicide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C7H3BrF3I

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On October 12, 2017, Patil, Rakesh Ishwar; Gunjal, Amol Pandurang; Verma, Jeevan; Kumar, Puneet; Rai, Santosh Kumar; Rai, Himanshu; Kumar, Anil published a patent.Synthetic Route of 364-12-5 The title of the patent was Preparation of heterocyclic compounds as GPR119 agonist for treatment of metabolic disorders. And the patent contained the following:

The invention relates to novel compounds of formula I as GPR119 agonist, compositions containing such compounds and method of their preparation which are useful for the prevention or treatment of metabolic disorders including diabetes mellitus type I and type II. I [wherein X1, X2, X3, X4, and X5 independently = N, O, S, or CH; R1 and R2 independently = H, O, C1-6alkyl, amino, etc.; A = tetrazol-1-ylphenyl-, 4-dimethylaminocarbonyl-Ph, 1-benzyl-piperazin-4-yl, etc.; B = morpholin-4-ylcarbonyl-Ph, -CH2OH, 4-cyano-Ph, etc.; n = 0, 1, 2, or 3] or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof, are claimed and exemplified. Example compound II was prepared from the oxidation of the corresponding sulfanyl intermediate in 37.62% yield. Exemplified I were evaluated for antidiabetic activity using an oral glucose tolerance test in mice and Sprague-Dawley rats from which II demonstrated dose-dependent reduction of glucose at 3mpk and 10mpk. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Synthetic Route of 364-12-5

The Article related to heterocyclic compound preparation gpr119 metabolic disease diabetes, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On December 3, 2020, Hopper, Allen Taylor; Mischke, Steven; La, Daniel published a patent.HPLC of Formula: 1012882-90-4 The title of the patent was Cyanopiperiddine compounds as CYP46A1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Described herein are cyanopiperidine compounds I that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salts thereof. Specifically, the invention relates to compounds of formula I wherein R1 is (un)substituted C6-10 aryl, (un)substituted C3-7 cycloalkyl, (un)substituted 3- to 7-membered heterocyclic ring, etc.; X is (CH2)0-2; Y is (CRaRb)0-4; Ra and Rb are independently H, halo, CN, OH, NO2, NH2 and derivatives, C1-6 alkyl, etc.; R7-R10 are independently H, C1-6 (halo)alkyl, C1-6 (halo)alkoxy, etc.; each of the R2 and R3 are independently halo, CN OH, NO2, NH2 and derivatives, C1-6 alkyl, C3-7 cycloalkyl, etc.; ring A is 5- to 6-membered N-containing heteroaryl; ring B is C6-10 aryl, 5- to 6-membered heteroaryl; and their pharmaceutically acceptable salts as CYP46A1 inhibitors in the treatment of diseases thereof, are claimed. Example compound II was prepared by using olefination, heterocyclization, and amidation as the key steps. All the invention compounds were evaluated for their CYP46A1 inhibitory activity. The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).HPLC of Formula: 1012882-90-4

The Article related to cyano piperiddine preparation cyp46a1 inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 1012882-90-4

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com